IAN MORTIMER, the PRESIDENT of $XENE, sold 25,000 shares of the company on 10-01-2025 for an estimated $1,003,999. We received data on the trade from a recent SEC filing. This was a sale of approximately 44.4% of their shares of this class of stock. Following this trade, they now own 31,302 shares of this class of $XENE stock.
$XENE Insider Trading Activity
$XENE insiders have traded $XENE stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- IAN MORTIMER (PRESIDENT, CEO & INTERIM CFO) sold 25,000 shares for an estimated $1,003,999
- STEVEN GANNON sold 3 shares for an estimated $91
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XENE Hedge Fund Activity
We have seen 113 institutional investors add shares of $XENE stock to their portfolio, and 96 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,329,202 shares (+163.5%) to their portfolio in Q2 2025, for an estimated $104,204,022
- HOLOCENE ADVISORS, LP added 1,809,475 shares (+inf%) to their portfolio in Q2 2025, for an estimated $56,636,567
- WELLINGTON MANAGEMENT GROUP LLP removed 1,614,436 shares (-42.6%) from their portfolio in Q2 2025, for an estimated $50,531,846
- CAPITAL WORLD INVESTORS removed 1,568,978 shares (-70.5%) from their portfolio in Q2 2025, for an estimated $49,109,011
- STATE STREET CORP added 1,074,840 shares (+351.7%) to their portfolio in Q2 2025, for an estimated $33,642,492
- SAMLYN CAPITAL, LLC removed 1,016,381 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $31,812,725
- GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares (+1294.2%) to their portfolio in Q2 2025, for an estimated $28,193,349
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XENE Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 09/02/2025
- Wedbush issued a "Outperform" rating on 08/12/2025
- Chardan Capital issued a "Buy" rating on 08/12/2025
- Evercore ISI Group issued a "Outperform" rating on 05/14/2025
- Wells Fargo issued a "Overweight" rating on 05/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/13/2025
- Needham issued a "Buy" rating on 05/13/2025
To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.
$XENE Price Targets
Multiple analysts have issued price targets for $XENE recently. We have seen 9 analysts offer price targets for $XENE in the last 6 months, with a median target of $53.0.
Here are some recent targets:
- Benjamin Burnett from Wells Fargo set a target price of $48.0 on 09/03/2025
- Brian Abrahams from RBC Capital set a target price of $55.0 on 09/02/2025
- Laura Chico from Wedbush set a target price of $43.0 on 08/12/2025
- Rudy Li from Chardan Capital set a target price of $55.0 on 08/12/2025
- Cory Kasimov from Evercore ISI Group set a target price of $55.0 on 05/14/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $53.0 on 05/13/2025
- Serge Belanger from Needham set a target price of $55.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
